guest ::
| Home > Publications Database > Chapter 4 - Therapies for prion diseases > print |
| 001 | 145422 | ||
| 005 | 20200925153819.0 | ||
| 037 | _ | _ | |a DZNE-2020-00765 |
| 041 | _ | _ | |a English |
| 100 | 1 | _ | |a Zafar, Saima |0 P:(DE-2719)9000358 |b 0 |e First author |
| 245 | _ | _ | |a Chapter 4 - Therapies for prion diseases |
| 260 | _ | _ | |c 2019 |b Elsevier |
| 295 | 1 | 0 | |a Handbook of Clinical Neurology |
| 300 | _ | _ | |a 47 - 58 |
| 336 | 7 | _ | |a BOOK_CHAPTER |2 ORCID |
| 336 | 7 | _ | |a Book Section |0 7 |2 EndNote |
| 336 | 7 | _ | |a bookPart |2 DRIVER |
| 336 | 7 | _ | |a INBOOK |2 BibTeX |
| 336 | 7 | _ | |a Output Types/Book chapter |2 DataCite |
| 336 | 7 | _ | |a Contribution to a book |b contb |m contb |0 PUB:(DE-HGF)7 |s 1596806700_19233 |2 PUB:(DE-HGF) |
| 490 | 0 | _ | |v 165 |
| 520 | _ | _ | |a Recent advances in understanding of the molecular biology of prion diseases and improved clinical diagnostic techniques might allow researchers to think about therapeutic trials in Creutzfeldt–Jakob disease (CJD) patients. Some attempts have been made in the past and various compounds have been tested in single case reports and patient series. Controlled trials are rare. However, in the past few years, it has been demonstrated that clinical trials are feasible. The clinicians might face several specific problems when evaluating the efficacy of the drug in CJD, such as rareness of the disease, lack of appropriate preclinical tests and heterogeneous clinical presentation in humans. These problems have to be carefully addressed in future. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 700 | 1 | _ | |a Noor, Aneeqa |0 P:(DE-2719)9001208 |b 1 |
| 700 | 1 | _ | |a Zerr, Inga |0 P:(DE-2719)2000058 |b 2 |e Last author |
| 856 | 4 | _ | |u https://reader.elsevier.com/reader/sd/pii/B9780444640123000046?token=BF53112E5F74549C7D447FFE586AF06B4B7E8F2A2811F9F03F7D5879F145D9EF121866DF45FA837E234B047CA240829A |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:145422 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000358 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9001208 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2000058 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |2 G:(DE-HGF)POF3-300 |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2019 |
| 920 | 1 | _ | |0 I:(DE-2719)5000037 |k Ext UMG Zerr |l Ext UMG Zerr |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)6000014 |k Göttingen Pre 2020 |l Göttingen Pre 2020 |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1440011-1 |k AG Zerr |l Translational Studies and Biomarkers |x 2 |
| 980 | _ | _ | |a contb |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)5000037 |
| 980 | _ | _ | |a I:(DE-2719)6000014 |
| 980 | _ | _ | |a I:(DE-2719)1440011-1 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|